Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.

摘要: This ongoing phase I study sought to establish the maximum tolerated dose of combination carboplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given without routine growth factor support previously untreated patients with stage IIIB IV non-small cell lung cancer. Paclitaxel was administered as a 3-hour intravenous infusion. The infusion over 30 minutes immediately afterward. Patients were assigned sequentially one eight treatment groups in which doses ranging from 130 185 mg/m2 230 350 mg/m2, respectively. Twenty-four have been treated date, has reached at mg/m2. an excellent safety profile, only few, short-lasting episodes neutropenia observed no evidence infection. At tested, thrombocytopenia not occurred.